Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 25Unknown 10Terminated 8Active not recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 129Cyclophosphamide 122Doxorubicin 62Vincristine 61venetoclax 59Prednisone 57ibrutinib 52Specimen Handling 50fludarabine 47Lenalidomide 47Biopsy 46obinutuzumab 44acalabrutinib 43Etoposide 41fludarabine phosphate 36Magnetic Resonance Spectroscopy 36Cytarabine 35CT-P10 35Dexamethasone 34Methotrexate 29Bendamustine Hydrochloride 27pembrolizumab 26Nivolumab 22blinatumomab 21zanubrutinib 20prednylidene 19Calcium Dobesilate 19deltacortene 18Radiotherapy 18Melphalan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Chlorambucil × Lymphoid × Clear all
NCT03462719 2026-05-08

GLOW

Janssen Research & Development, LLC

Phase 3 Active not recruiting
211 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca

Phase 3 Active not recruiting
155 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01808599 2026-01-15

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Active not recruiting
112 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

Acerta Pharma BV

Phase 3 Active not recruiting
535 enrolled 19 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡